Cevimeline hydrochloride hemihydrate is primarily used in the treatment of dry mouth symptoms associated with Sjögren's syndrome, an autoimmune disorder that affects the salivary and lacrimal glands. It works by stimulating the salivary glands to produce more saliva, thereby alleviating discomfort and improving oral health. This medication is also beneficial in managing dry mouth caused by radiation therapy in head and neck cancer patients. By enhancing saliva secretion, it helps in reducing the risk of dental caries, oral infections, and difficulties in speaking and swallowing. Additionally, it may be prescribed off-label for other conditions involving reduced saliva production. Proper dosage and medical supervision are essential to minimize potential side effects such as sweating, nausea, and gastrointestinal disturbances.